PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Biostatistics Research Branch, National Institute Allergy and Infectious Diseases, Bethesda, MD, USA.\', \'Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.\', \'Center for Medical Statistics, Informatics and Intelligent Systems; Medical University of Vienna, Vienna, Austria.\', \'Department of Medicine (Rheumatology, Allergy, and Immunology Section) and Department of Immunobiology, Yale University, New Haven, CT, USA.\', \'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.\', \'The Emmes Company, LLC, Rockville, MD, USA.\', \'Université de Paris, IAME, Inserm, Paris, France.\', \'AP-HP, Hôpital Bichat, DEBRC, Paris, France.\', \'Center of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China.\', \'China-Japan Friendship Hospital, Department of Respiratory Medicine, Capital Medical University, Beijing, China.\', \'Department of Mathematics and Statistics, Lancaster University, Lancaster, UK.\', \'MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1177/1740774520939938
?:doi
?:hasPublicationType
?:journal
  • Clinical trials (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 32674594
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Endpoints for randomized controlled clinical trials for COVID-19 treatments.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all